Olaptesed pegol: Interim Phase IIa data

Interim data from a pilot group of 9 evaluable patients with relapsed CLL in an open-label, dose-escalation, European Phase IIa trial showed that 1, 2 and 4 mg/kg NOX-A12 in combination with

Read the full 323 word article

How to gain access

Continue reading with a
two-week free trial.